NRAS and melanoma: Clinical trials assessing the efficacy of MEKi PD0325901 (PD901), binimetinib and trametinib as single agents have produced modest results in patients with NRAS-mutant melanoma (1, 12), highlighting the need for agents that can improve the durability of this response.